Previous 10 | Next 10 |
2024-03-28 07:15:01 ET Goldman Sachs analyst issues BUY recommendation for MRNA on March 28, 2024 05:33AM ET. The previous analyst recommendation was Buy. MRNA was trading at $110.59 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
2024-03-28 05:55:00 ET Cathie Wood's latest stocks shopping spree included several healthcare innovators -- and she picked them up for a bargain. Wood isn't intimidated by shares that have wallowed in the doldrums because she favors long-term investing. The idea is to buy promising companie...
2024-03-27 17:55:17 ET Summary Moderna, Inc. held an investor event today to discuss its vaccines program and business updates. The company had a rough year in 2023, making a $4.7bn loss, after an >$8bn profit in the prior year. With sales of SpikeVax destined to fall furth...
2024-03-27 09:23:00 ET U.S. stock index futures on Wednesday pointed to a higher open, suggesting a rebound in equities following a lower finish in the previous session. Here are some stocks to watch on Wednesday: ... Read the full article on Seeking Alpha For further d...
2024-03-27 07:30:03 ET UBS analyst issues BUY recommendation for MRNA on March 27, 2024 06:16AM ET. The previous analyst recommendation was Buy. MRNA was trading at $107.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst r...
2024-03-27 07:15:55 ET More on Moderna Moderna, Inc. (MRNA) Barclays 26th Annual Global Healthcare Conference (Transcript) Moderna, Inc. (MRNA) TD Cowen 44th Annual Health Care Conference (Transcript) Moderna: Counting On Pipeline Too Much Moderna succeeds in...
Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints Expects two more Phase 3 readouts in 2024, including combination vaccine against flu and COVID-19, and vaccine against CMV Announces positive clinical trial data...
2024-03-26 08:15:09 ET More on Moderna Moderna, Inc. (MRNA) Barclays 26th Annual Global Healthcare Conference (Transcript) Moderna, Inc. (MRNA) TD Cowen 44th Annual Health Care Conference (Transcript) Moderna: Counting On Pipeline Too Much Another update to C...
mRNA-1283 induced a more robust immune response compared to Spikevax ® COVID-19 vaccine, mRNA-1273.222 Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-10...
2024-03-22 15:00:00 ET More on the markets Wall Street Lunch: Fed Not Spooked By Recent Inflation SPY: Don't Fall For The Greed SPY: Assessing Economic Risks And Market Trends (Technical Analysis, Rating Downgrade) Investors sell $66B worth of money market fu...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...